134528-32-8

Basic information

• Product Name: 1-beta-D-arabinofuranosyl-5-[(Z)-2-bromoethenyl]pyrimidine-2,4(1H,3H)-dione
• CAS NO: 134528-32-8
• Molecular Formula: C₁₁H₁₃BrN₂O₆
• Molecular Weight: 349.1347
• Mol File: 134528-32-8.mol
• Article Data: 6

Chemical Properties

• Density: 1.979g/cm³
• Refractive Index: 1.746
• CAS DataBase Reference: 1-beta-D-arabinofuranosyl-5-[(Z)-2-bromoethenyl]pyrimidine-2,4(1H,3H)-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 1-beta-D-arabinofuranosyl-5-[(Z)-2-bromoethenyl]pyrimidine-2,4(1H,3H)-dione(134528-32-8)
• EPA Substance Registry System: 1-beta-D-arabinofuranosyl-5-[(Z)-2-bromoethenyl]pyrimidine-2,4(1H,3H)-dione(134528-32-8)

Safety Data

• Hazardous Substances Data: 134528-32-8(Hazardous Substances Data)

Upstream product

• 86359-94-6 Acetic acid (2R,3S,4R,5R)-4-acetoxy-5-acetoxymethyl-2-[5-((Z)-2-bromo-vinyl)-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl]-tetrahydro-furan-3-yl ester 
• 87877-27-8 1-(2,3,5-tri-O-acetyl-β-D-arabinofuranosyl)-5-(E)-2-(bromovinyl)uracil 
• 132054-88-7 1-(2,3,5-tri-O-acetyl-β-D-arabinofuranosyl)-5-(Z)-<2-(trimethylsilyl)vinyl>uracil 
• 95119-95-2 3-(1-(β-D-arabinofuranosyl)uracil-5-yl)-acrylic acid 
• 162239-37-4 1-<(β-L-arabinofuranosyl)-E-5-(2-carboxyvinyl)>uracil 
• 31501-46-9 (2S,3S,3aR,9aS)-3-hydroxy-2-(hydroxymethyl)-2,3,3a,9a-tetrahydro-6H-furo[2,3’:4,5]oxazolo[3,2-a]pyrimidin-6-one 
• 162239-36-3 1-<(β-L-arabinofuranosyl)-E-5-(2-methoxycarbonylvinyl)>uracil 
• 162239-34-1 1-(β-L-arabinofuranosyl)-5-iodouracil 
• 58-96-8 1-(β-L-arabinofuranosyl)-uracil 

Downstream Products

• 150464-65-6 1-(2,3,5-tri-O-benzoyl-β-D-arabinofuranosyl)-5(E)-(2-bromovinyl)uracil 
• 80434-16-8 5-((Z)-2-Bromo-vinyl)-1-((2R,3S,4S,5R)-3,4-dihydroxy-5-hydroxymethyl-tetrahydro-furan-2-yl)-1H-pyrimidine-2,4-dione 

Relevant articles and documents

NUCLEOSIDES FOR SUPPRESSING OR REDUCING THE DEVELOPMENT OF RESISTANCE IN CYTOSTATIC THERAPY

The invention relates to special nucleosides, for example, a nucleoside of the formula I, wherein R1-R5 are as described herein, and also to drugs which contain these nucleosides. Furthermore, the invention relates to the use of such nucleosides in a method for suppressing or reducing the formation of resistance in the case of cytostatic treatment of a cancer patient.

Nucleoside analogue phosphates for topical use

Compositions for topical use in herpes virus infections comprising anti-herpes nucleoside analogue phosphate esters, such as acyclovir monophosphate, acyclovir diphosphate, and acyclovir triphosphate which show increased activity against native strains of herpes virus as well as against resistant strains, particularly thymidine kinase negative strains of virus. Also disclosed are methods for treatment of herpes infections with nucleoside phosphates. Anti-herpes nucleoside analogues phosphate esters include the phosphoramidates and phosphothiorates, as well as polyphosphates comprising C and S bridging atoms.

Facile access to 2′-O-acyl prodrugs of 1- (β-D-arabinofuranosyl)-5(E)-(2-bromovinyl)uracil (BVAraU) via regioselective esterase-catalyzed hydrolysis of 2′ 3′, 5′-triesters

Treatment of 1-(2,3,5-tri-O-acetyl-β-D-arabinofuranosyl) -5-[2-(trimethylsilyl)-vinyl]uracil (3) with pyridinium bromide perbromide and deacetylation gave BVAraU (2). Pig liver esterase (EC 3.1.1.1) catalysed the regioselective hydrolysis of 1-